Annexin A1 restores Aβ1-42-induced blood–brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway

Aging Cell

Volumn 16, Issue 1, 2017, Pages 149-161

  Park, Jong Chan ^a   Baik, Sung Hoon ^a   Han, Sun Ho ^a   Cho, Hyun Jin ^a   Choi, Hyunjung ^a   Kim, Haeng Jun ^a   Choi, Heesun ^a   Lee, Wonik ^a   Kim, Dong Kyu ^a   Mook Jung, Inhee ^a  

^a Seoul National University   (South Korea)

Author keywords

5XFAD mice; Alzheimer's disease; Annexin A1; blood brain barrier; endothelial cell; pericyte; amyloid

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CLAUDIN 5; GUANOSINE TRIPHOSPHATE; LIPOCORTIN 1; PROTEIN FPR2; PROTEIN INHIBITOR; PROTEIN ZO1; RECEPTOR; RECOMBINANT LIPOCORTIN 1; RECOMBINANT PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); FORMYLPEPTIDE RECEPTOR; FPR2 PROTEIN, HUMAN; LIPOXIN RECEPTOR; PEPTIDE FRAGMENT;

5XFAD MOUSE; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CAPILLARY ENDOTHELIAL CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; MALE; MEMBRANE DAMAGE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN SECRETION; SERUM; SIGNAL TRANSDUCTION; TIGHT JUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CAPILLARY; DRUG EFFECTS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANNEXIN A1; BLOOD-BRAIN BARRIER; CAPILLARIES; FEMALE; HUMANS; MALE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PERICYTES; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; RECOMBINANT PROTEINS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS;

EID: 84987906247     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12530     Document Type: Article

References (45)

1. Ballabh P, Braun A, Nedergaard M (2004) The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1–13.
2. Banks WA (2008) The blood-brain barrier as a cause of obesity. Curr. Pharm. Des. 14, 1606–1614.
3. Barnham KJ, Masters CL, Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3, 205–214.
4. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68, 409–427.
5. Bien-Ly N, Boswell CA, Jeet S, Beach TG, Hoyte K, Luk W, Shihadeh V, Ulufatu S, Foreman O, Lu Y, DeVoss J, van der Brug M, Watts RJ (2015) Lack of widespread BBB disruption in Alzheimer's disease models: focus on therapeutic antibodies. Neuron 88, 289–297.
6. Black MD, Carey F, Crossman AR, Relton JK, Rothwell NJ (1992) Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat. Brain Res. 585, 135–140.
7. Butt AM, Jones HC, Abbott NJ (1990) Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol. 429, 47–62.
8. Byun J, Son SM, Cha MY, Shong M, Hwang YJ, Kim Y, Ryu H, Moon M, Kim KS, Mook-Jung I (2015) CR6-interacting factor 1 is a key regulator in Abeta-induced mitochondrial disruption and pathogenesis of Alzheimer's disease. Cell Death Differ. 22, 959–973.
9. Chatterjee S, Naik UP (2012) Pericyte-endothelial cell interaction: a survival mechanism for the tumor vasculature. Cell Adh. Migr. 6, 157–159.
10. Chen F, Radisky ES, Das P, Batra J, Hata T, Hori T, Baine AM, Gardner L, Yue MY, Bu G, del Zoppo G, Patel TC, Nguyen JH (2013) TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure. J. Cereb. Blood Flow Metab. 33, 1041–1049.
11. Cristante E, McArthur S, Mauro C, Maggioli E, Romero IA, Wylezinska-Arridge M, Couraud PO, Lopez-Tremoleda J, Christian HC, Weksler BB, Malaspina A, Solito E (2013) Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications. Proc. Natl Acad. Sci. USA 110, 832–841.
12. Erickson MA, Banks WA (2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J. Cereb. Blood Flow Metab. 33, 1500–1513.
13. Fenton K (2006) Sepsis and the BBB: brain injury, biomarkers, and the bedside. Crit. Care Med. 34, 2022–2023.
14. Gray MT, Woulfe JM (2015) Striatal blood-brain barrier permeability in Parkinson's disease. J. Cereb. Blood Flow Metab. 35, 747–750.
15. Hawkins RA, Peterson DR, Vina JR (2002) The complementary membranes forming the blood-brain barrier. IUBMB Life 54, 101–107.
16. He N, Jin WL, Lok KH, Wang Y, Yin M, Wang ZJ (2013) Amyloid-beta(1-42) oligomer accelerates senescence in adult hippocampal neural stem/progenitor cells via formylpeptide receptor 2. Cell Death Dis. 4, e924.
17. Hohsfield LA, Humpel C (2015) Migration of blood cells to beta-amyloid plaques in Alzheimer's disease. Exp. Gerontol. 65, 8–15.
18. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, Narumiya S (2000) Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57, 976–983.
19. Koenig H, Trout JJ, Goldstone AD, Lu CY (1992) Capillary NMDA receptors regulate blood-brain barrier function and breakdown. Brain Res. 588, 297–303.
20. Kook SY, Hong HS, Moon M, Ha CM, Chang S, Mook-Jung I (2012) Abeta(1)(-)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca(2)(+)-calcineurin signaling. J. Neurosci. 32, 8845–8854.
21. Kosicka A, Cunliffe AD, Mackenzie R, Zariwala MG, Perretti M, Flower RJ, Renshaw D (2013) Attenuation of plasma annexin A1 in human obesity. FASEB J. 27, 368–378.
22. LaBarbera KE, Hyldahl RD, O'Fallon KS, Clarkson PM, Witkowski S (2015) Pericyte NF-kappaB activation enhances endothelial cell proliferation and proangiogenic cytokine secretion in vitro. Physiol. Rep. 3, 1–11.
23. Locatelli I, Sutti S, Jindal A, Vacchiano M, Bozzola C, Reutelingsperger C, Kusters D, Bena S, Parola M, Paternostro C, Bugianesi E, McArthur S, Albano E, Perretti M (2014) Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. Hepatology 60, 531–544.
24. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN, Group AR (2010). Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. J. Alzheimers Dis. 20, 1233–1242.
25. Luo ZZ, Gao Y, Sun N, Zhao Y, Wang J, Tian B, Shi J (2014) Enhancing the interaction between annexin-1 and formyl peptide receptors regulates microglial activation to protect neurons from ischemia-like injury. J. Neuroimmunol. 276, 24–36.
26. Mann GE, Zlokovic BV, Yudilevich DL (1985) Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon. Biochim. Biophys. Acta 819, 241–248.
27. McArthur S, Cristante E, Paterno M, Christian H, Roncaroli F, Gillies GE, Solito E (2010) Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia. J. Immunol. 185, 6317–6328.
28. Minagar A, Alexander JS (2003) Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9, 540–549.
29. van Nieuw Amerongen GP, van Hinsbergh VW (2007) Endogenous RhoA inhibitor protects endothelial barrier. Circ. Res. 101, 7–9.
30. van Nieuw Amerongen GP, van Delft S, Vermeer MA, Collard JG, van Hinsbergh VW (2000) Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ. Res. 87, 335–340.
31. Pardridge WM (2012) Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 32, 1959–1972.
32. Park R, Kook SY, Park JC, Mook-Jung I (2014) Abeta1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-kappaB signaling. Cell Death Dis. 5, e1299.
33. Perretti M, D'Acquisto F (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 9, 62–70.
34. Perretti M, Flower RJ (2004) Annexin 1 and the biology of the neutrophil. J. Leukoc. Biol. 76, 25–29.
35. Petratos S, Li QX, George AJ, Hou X, Kerr ML, Unabia SE, Hatzinisiriou I, Maksel D, Aguilar MI, Small DH (2008) The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. Brain 131, 90–108.
36. Shang X, Marchioni F, Sipes N, Evelyn CR, Jerabek-Willemsen M, Duhr S, Seibel W, Wortman M, Zheng Y (2012) Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem. Biol. 19, 699–710.
37. Shang X, Marchioni F, Evelyn CR, Sipes N, Zhou X, Seibel W, Wortman M, Zheng Y (2013) Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc. Natl Acad. Sci. USA 110, 3155–3160.
38. Shimojima N, Eckman CB, McKinney M, Sevlever D, Yamamoto S, Lin W, Dickson DW, Nguyen JH (2008) Altered expression of zonula occludens-2 precedes increased blood-brain barrier permeability in a murine model of fulminant hepatic failure. J. Invest. Surg. 21, 101–108.
39. Solito E, McArthur S, Christian H, Gavins F, Buckingham JC, Gillies GE (2008) Annexin A1 in the brain–undiscovered roles? Trends Pharmacol. Sci. 29, 135–142.
40. Son SM, Byun J, Roh SE, Kim SJ, Mook-Jung I (2014) Reduced IRE1alpha mediates apoptotic cell death by disrupting calcium homeostasis via the InsP3 receptor. Cell Death Dis. 5, e1188.
41. Texido L, Martin-Satue M, Alberdi E, Solsona C, Matute C (2011) Amyloid beta peptide oligomers directly activate NMDA receptors. Cell Calcium 49, 184–190.
42. Tsai WH, Shih CH, Yu YB, Hsu HC (2013) Plasma levels in sepsis patients of annexin A1, lipoxin A4, macrophage inflammatory protein-3a, and neutrophil gelatinase-associated lipocalin. J. Chin. Med. Assoc. 76, 486–490.
43. Vong L, Ferraz JG, Dufton N, Panaccione R, Beck PL, Sherman PM, Perretti M, Wallace JL (2012) Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One 7, e39244.
44. Yazawa H, Yu ZX, Le Takeda, Y, Gong W, Ferrans VJ, Oppenheim JJ, Li CC, Wang JM (2001) Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J. 15, 2454–2462.
45. Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV (2015) Establishment and dysfunction of the blood-brain barrier. Cell 163, 1064–1078.